^
Association details:
| Biomarker: | FGFR3-BAIAP2L1 fusion |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
In vitro and in vivo investigations of anlotinib in bladder cancer treatment.
Published date:
05/26/2022
Excerpt:
To assess the roles of anlotinib in bladder cancer, we treated SW780 cell line which had FGFR3-BALAP2L1 fusion mutation and UMUC-14 cell line which had a FGFR3 (MuS247C) mutation with DMSO, anlotinib and erdafitinib....Compared with erdafitinib, the inhibitory ability of anlotinib was weaker than that of erdafitinib in cell line with FGFR3 (MuS247C) mutation, on the contrary, it was much stronger in cell line with FGFR3-BALAP2L1 fusion mutation.
DOI:
10.1200/JCO.2022.40.16_suppl.e16505
